Contract Signing between EU and Novavax for Covid-19 Vaccines

Stella Kyriakides, European Commissioner for Health and Food Safety, signed a new contract between the European Commission and the pharmaceutical company Novavax. This is the seventh Advanced Purchase Agreement (APA) with a pharmaceutical company to ensure access to a potential vaccine against COVID-19 during the fourth quarter of 2021 and 2022. Under this contract, member states will be able to purchase up to 100 million doses of the Novavax vaccine, with the option to purchase an additional 100 million doses during the years 2021, 2022, and 2023, after this vaccine has been tested and approved by the European Medicines Agency as safe and effective.